FDA General

Infusion made from deceased donor pancreatic islet cells

Members push aside data concerns, endorse retinoid for fibrodysplasia ossificans progressiva

First therapy approved for anti-AChR-positive and anti-MuSK antibody-positive patients

Challenges of drug development in fibrodysplasia ossificans progressiva on full display

A brief assessment in primary care can help identify patients most at risk

Ritlecitinib led to 80% scalp coverage at 6 months in nearly a fourth of adolescents and adults

Health news and commentary from around the Web gathered by MedPage Today staff

Screening, administration, and eligibility concerns remain

Sarepta's treatment gets a nod for ambulatory pediatric patients

Warrior Labz SARMS markets several drugs they claim could address weight loss, muscle growth

Health news and commentary from around the Web gathered by MedPage Today staff

Now another oral option other than metformin

Repurposed anti-inflammatory drug may be used alone or in combination with standard meds

Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate